1,293
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLES: GASTROINTESTINAL CANCER

Significance of baseline FDG-PET/CT scan as a method of staging regional lymph nodes in patients with operable distal oesophageal or gastroesophageal junction adenocarcinoma

, , , , , , , , & show all
Pages 1224-1232 | Received 25 Jan 2017, Accepted 02 May 2017, Published online: 19 May 2017

References

  • Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1:505–527.
  • Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.
  • Rubenstein JH, Shaheen NJ. Epidemiology, diagnosis, and management of esophageal adenocarcinoma. Gastroenterology. 2015;149:302–317.
  • Fischer C, Lingsma H, Hardwick R, et al. Risk adjustment models for short-term outcomes after surgical resection for oesophagogastric cancer. Br J Surg. 2016;103:105–116.
  • Rice TW, Ishwaran H, Blackstone EH, et al. Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 2016;29:913–919.
  • Blom RL, Steenbakkers IR, Lammering G, et al. PET/CT-based metabolic tumour volume for response prediction of neoadjuvant chemoradiotherapy in oesophageal carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:1500–1506.
  • Hong D, Lunagomez S, Kim EE, et al. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer. 2005;104:1620–1626.
  • Miyata H, Yamasaki M, Makino T, et al. Impact of number of [(18)F]fluorodeoxyglucose-PET-positive lymph nodes on survival of patients receiving neoadjuvant chemotherapy and surgery for oesophageal cancer. Br J Surg. 2016;103:97–104.
  • Gillies RS, Middleton MR, Han C, et al. Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma. Br J Surg. 2012;99:239–245.
  • Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162:55–63.
  • Suzuki A, Xiao L, Hayashi Y, et al. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer. 2011;117:4823–4833.
  • Jayachandran P, Pai RK, Quon A, et al. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;84:471–477.
  • Elliott JA, O'farrell NJ, King S, et al. Value of CT-PET after neoadjuvant chemoradiation in the prediction of histological tumour regression, nodal status and survival in oesophageal adenocarcinoma. Br J Surg. 2014;101:1702–1711.
  • Suzuki A, Xiao L, Taketa T, et al. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. Ann Oncol. 2013;24:2854–2859.
  • Davies L, Mason JD, Roberts SA, et al. Prognostic significance of total disease length in esophageal cancer. Surg Endosc. 2012;26:2810–2816.
  • Twine CP, Roberts SA, Rawlinson CE, et al. Prognostic significance of the endoscopic ultrasound defined lymph node metastasis count in esophageal cancer. Dis Esophagus. 2010;23:652–659.
  • Lee WC, Lee TH, Jang JY, et al. Staging accuracy of endoscopic ultrasound performed by nonexpert endosonographers in patients with resectable esophageal squamous cell carcinoma: is it possible? Dis Esophagus. 2015;28:574–578.
  • Miyata H, Yamasaki M, Takahashi T, et al. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET). Ann Surg Oncol. 2014;21:575–582.
  • Kauppi JT, Oksala N, Salo JA, et al. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT. Acta Oncol. 2012;51:636–644.
  • Kim SJ, Koo PJ, Chang S. Predictive value of repeated F-18 FDG PET/CT parameters changes during preoperative chemoradiotherapy to predict pathologic response and overall survival in locally advanced esophageal adenocarcinoma patients. Cancer Chemother Pharmacol. 2016;77:723–731.
  • Swisher SG, Erasmus J, Maish M, et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004;101:1776–1785.
  • Ajani JA, Correa AM, Hofstetter WL, et al. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2012;23:2638–2642.
  • Tan S, Kligerman S, Chen W, et al. Spatial-temporal [18F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2013;85:1375–1382.
  • Zhu W, Xing L, Yue J, et al. Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation: a systematic review and meta-analysis. Br J Radiol. 2012;85:e694–e701.
  • Schollaert P, Crott R, Bertrand C, et al. A systematic review of the predictive value of (18)FDG-PET in esophageal and esophagogastric junction cancer after neoadjuvant chemoradiation on the survival outcome stratification. J Gastrointest Surg. 2014;18:894–905.
  • Heneghan HM, Donohoe C, Elliot J, et al. Can CT-PET and endoscopic assessment post-neoadjuvant chemoradiotherapy predict residual disease in esophageal cancer? Ann Surg. 2016;264:831–838.
  • Arnett AL, Merrell KW, Macintosh EM, et al. Utility of (18)F-FDG PET for predicting histopathologic response in esophageal carcinoma following chemoradiation. J Thorac Oncol. 2017;12:121–128.
  • Fencl P, Belohlavek O, Harustiak T, et al. FDG-PET/CT lymph node staging after neoadjuvant chemotherapy in patients with adenocarcinoma of the esophageal-gastric junction. Abdom Radiol (NY). 2016;41:2089–2094.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.